FDA denies approval of Regeneron’s linvoseltamab for multiple myeloma, cites third-party issues
The regulator’s Complete Response Letter flagged problems at a third-party fill/finish site, which Regeneron says it has already addressed. The manufacturing facility is currently awaiting reinspection.